Fox Chase Cancer Center News

PHILADELPHIA (November 13, 2020) – In a recently published paper, researchers at Fox Chase Cancer Center unveiled data that suggested possible new targets for the treatment of T-acute leukemia/lymphoma (T-ALL).

PHILADELPHIA (November 5, 2020) – Researchers at Fox Chase Cancer Center have harnessed the power of the Nobel Prize-winning CRISPR/Cas9 technology to identify cellular factors involved in resistance to sunitinib by clear cell renal cell carcinoma.

PHILADELPHIA (November 4, 2020)—Fox Chase Cancer Center has become the first cancer center in the Northeast to feature a new tumor marker technology that has been described as the next generation of surgical navigation, one that will make breast excisional biopsies and breast-conserving surgeries more precise.

PHILADELPHIA (October 30, 2020) – In a study released online today, researchers at Fox Chase Cancer Center have identified a new biomarker and potential novel treatment target for pancreatic ductal adenocarcinoma (PDAC) that could help starve cancer cells and allow the immune system to attack the tumor.

PHILADELPHIA (October 30, 2020) – Pathogenic variants in DNA damage response and repair (DDRR) genes have been identified in patients with early onset renal cancer, according to a recent study by researchers at Fox Chase Cancer Center.

PHILADELPHIA (October 29, 2020)—Researchers from Fox Chase Cancer Center have presented new data indicating that several factors, the most significant one being pain, are significantly associated with a reduction in the number of working days per week in patients who attempt to work while receiving radiation treatment for head and neck cancer (HNC).

PHILADELPHIA (October 26, 2020)— Fox Chase Cancer Center is proud to support the Pancreatic Cancer Action Network (PanCAN) for PurpleStride Philadelphia 2020. Fox Chase will participate virtually with pancreatic cancer survivors, their loved ones, caregivers, and researchers on Saturday, November 7, 2020, to raise money for pancreatic cancer research and patient services.

PHILADELPHIA (October 26, 2020)—Researchers from Fox Chase Cancer Center have presented new data that shows that moderately hypofractionated photon and proton therapies are both safe for patients with low- or intermediate-risk prostate cancer.